CSF β-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: The effect of APOE ε4 allele

Neuroscience Letters

Volumn 440, Issue 2, 2008, Pages 145-149

  Smach, Mohamed Ali ^a   Charfeddine, Bassem ^a   Lammouchi, Turkia ^b   Harrabi, Imed ^c   Ben Othman, Leila ^a   Dridi, Hedi ^a   Bennamou, Soufien ^b   Limem, Khalifa ^a  

^a UNIVERSITY OF SOUSSE   (Tunisia)

^b SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

^c FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Amyloid; Alzheimer's disease; Apolipoprotein E; Risk factor; t tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON4; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; DEMENTIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; TAU PROTEINS;

EID: 45449090603     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.05.076     Document Type: Article

References (32)

1. Bernardi L., Maletta R.G., Tomaino C., Smirne N., Di Natale M., Perri M., Longo T., Colao R., Curcio S.A., Puccio G., Mirabelli M., Kawarai T., Rogaeva E., St George Hyslop P.H., Passarino G., De Benedictis G., and Bruni A.C. The effects of APOE and tau gene variability on risk of frontotemporal dementia. Neurobiol. Aging 27 (2006) 702-709
2. Blennow K., and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2 (2003) 605-613
3. Blennow K., and Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain. Res. Bull. 61 (2003) 235-242
4. Bosco P., Rodriguez R.-M.G., Anello G., Spada R.S., Romano A., Caraci F., Ferri R., and Guéant J.-L. Allele ε4 of APOE is a stronger predictor of Alzheimer risk in Sicily than in Continental South Italy. Neurosci. Lett. 388 (2005) 172-186
5. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., and van Duijn C.M. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease meta analysis consortium. JAMA. 278 (1997) 1349-1356
6. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss M.A., and Seubert P. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55 (1998) 937-945
7. S. Hajem, Le vieillissement de la population tunisienne, Un enjeu majeur pour le système sanitaire et social, 1 (2005) 307-308.
8. Hallman D.M., Boerwinkle E., Saha N., Sanholzer C., Menzel H.J., Csazar D., and Utermann G. The apolipoprotein E polymorphism: a comparison of allele frequencies effects in nine populations. Am. J. Hum. Genet. 49 (1991) 338-349
9. Hampel H., Teipel S.J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., Dodel R., Du Y., Farlow M., Moller H.-J., Bleennow K., and Buerger K. Value of CSF β-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiat. 9 (2004) 705-710
10. Herukka S.-K., Helisalmi S., Hallikainen M., Tervo S., Soininen H., and Pirttila T. CSFA β 42, tau and phosphorylated tau, APOE ε4 allele and MCI type in progressive MCI. Neurobiol. Aging 28 (2007) 507-514
11. Jellinger K.A., and Bancher C. Neuropathology of Alzheimer disease: a critical update. J. Neural Transm. Suppl. 54 (1998) 77-95
12. Jemaa R., Elasmi M., Feki M., Kallel A., Souissi M., Sanhaji H., Taieb H., Souheil O., and Kaabachi N. Apolipoprotein E polymorphism in the Tunisian population: frequency and effet on lipid parameters. Clin. Biochem. 39 (2006) 816-820
13. Jorm A.F., and Jolley D. The incidence of dementia: a meta-analysis. Neurology 51 (1998) 728-733
14. Lahlahi-Kacemi N., Bamou Y., and Guedira A. Polymorphisme de l'apolipoprotèine E dans une population marocaine: fréquence allélique et relation avec les paramètres lipidiques plasmatiques. Ann. Biol. Clin. 60 (2002) 73-78
15. Lambert J.C., Pasquier F., Cottel D., Frigard B., Amouyel P., and Chritier-harlin M.C. A new polymorphism in the ApoE promoter associated with risk of developing Alzheimer disease. Hum. Med. Genet. 3 (1998) 533-540
16. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K., Eikenberg O., Antzn C., Krause W.R., Reulbach U., Kornhuber J., and Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ 42, Aβ 42/Aβ 40 ratio and total tau. Neurobiol. Aging 25 (2004) 273-281
17. Liberoupoulos E., Milttiadous G., and Hatzivassiious M. Apolipoprotein E polymorphism in NorthWestern Greece: frequency and effect on lipid parameters. Ann. Clin. Lab. Sci. 3 (2004) 347-354
18. Luc G., Bard J.M., and Arceilrer D. Impact apolipoprotein E polymorphism on lipoproteins and risk myocardial infarction: the SCTIm study. Arterioscler. Thromb. 14 (1994) 1412-1419
19. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984) 939-944
20. Nitsch R., and Ohm T.G. Calretinin immunoreactive structures in the human hippocampal formation. J. Comp. Neurol. 360 (1995) 475-487
21. Nivet Antoine V., Coulhon M.P., Le Denmat C., Hamon B., Dulcire X., Lefebvre M., Piette F., Davous P., Durand D., and Duchassaing D. Maladies neurodégénératives et polymorphisme des gènes de l'apolipoprotéine E et de la bléomycine hydrolase. Ann. Biol. Clin. 61 (2003) 61-67
22. Noguchi M., Yoshita M., Matsumoto Y., Ono K., Iwasa K., and Yamada M. Decreased β amyloid peptide 42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J. Neurol. Sci. 237 (2005) 61-65
23. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., and Laferla F.M. A β immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 (2004) 321-332
24. Panza F., Solfrizzi V., Torres F., Mastroriann F., Parigi A.D., Colacco A.M., Basile A.M., Capurso C., Noya R., and Capurso A. Decrease frequency of allele from apolipoprotein E northern to southern Europe in Alzheimer's disease patients and centenarians. Neurosci. Lett. 277 (1999) 53-56
25. Piscopo P., Manfredi A., Malvezzi-Compeggi L., Crestini A., Spadoni O., Cherchi R., Deiana E., Piras M., and Confaloni A. Genetic study of sardinian patients with Alzheimer's disease. Neurosci. Lett. 398 (2006) 124-128
26. Raygani A.V., Zahrai M., Raygani A.V., Doosti M., Javadi E., Rezaei M., and Pourmotabbed T. Association between apolipoprotein E polymorphism and Alzheimer's disease in Tehran, Iran. Neurosci. Lett. 375 (2005) 1-6
27. Schoonenboom N.S.M., Pijnenburg Y.A.L., Mulder C., Rosso S.M., Van Elk E.-J., Van Kamp G.J., and Van Swieten J.C. Amyloid beta (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62 (2004) 1580-1584
28. Sjögren M., Andreasen N., and Blennow K. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. Clin. Chim. Acta 332 (2006) 1-10
29. Sunderland T., Mirza N., Putnam P., Linker G., Bhupali D., Durham R., Soares H., Kimmel L., Friendman D., Bergeson J., Csako G., Levy J.A., Bartko J.J., and Cohen R.M. Cerebrospinal fluid β amyloid 1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of ApoE ε4 allele. Biol. Psychiat. 56 (2004) 670-676
30. Tapiola T., Pirttila T., Mehta P.D., Alafuzoff I., Lehtovirta M., and Soininen H. Relationship between apoE genotype and CSF β amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol. Aging 21 (2000) 735-740
31. Tiret L., Deknijff P., Menzel H.J., Ehnholm C., Nicaud V., and Havekes L.M. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS study, European Atherosclerosis research study. Arterioscler. Thromb. Vasc. Biol. 14 (1994) 1617-1624
32. Valveny N., Esteban E., Kandi M.I., and Moral P. ApoE polymorphism in Spanish and Moroccan populations. Clin. Genet. 51 (1997) 354-356